

EMPOWER ANNOUNCES BRIDGE LOAN

SEATTLE, WA – December 31, 2018 – Empower Clinics Inc. (<https://empowerclinics.com>) (OTC: EPWCF; CSE: EPW; FRA 8EC) (the “Company”) today announces that it has agreed to obtain a bridge loan in the principal amount of CAD\$205,000 (the “Loan”) from Ty and Sons Investments Inc. (the “Lender”), an arm’s length party to the Company, to be evidenced by the issuance of a promissory note by the Company to the Lender. The Loan will bear interest at the rate of 6.0% per annum and will mature on January 31, 2020. The Company expects to use the proceeds of the Loan for internal restructuring purposes and for other general and administrative purposes.

EMPOWER CLINICS INC.

Per: “Craig Snyder”

Craig Snyder, Chief Executive Officer and Director

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable Canadian securities laws, including statements regarding the proposed use of proceeds of the Loan. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements, including factors that arise that result in the Company utilizing the proceeds of the Loan other than as described in this news release. Factors that could cause actual results to differ materially from these forward-looking statements include those risks set out in the Company’s public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.